
NYSE:CVS
This summary was created by AI, based on 9 opinions in the last 12 months.
CVS Health Corp has recently shown impressive growth, beating earnings and revenue expectations, which led to an 8% increase in its stock price, reaching a three-year high. Analysts are optimistic, suggesting an upside potential of around 22% towards the price target of $95.00. However, some experts caution that while the stock may appear cheap, it has faced challenges such as political decisions affecting Medicare rates and ongoing weaknesses in its retail pharmacy sector. Despite these concerns, CVS is reinventing itself, with significant improvements in its health insurance and pharmacy benefits divisions, reflecting an overall positive turnaround. The company's recent performance includes a solid revenue growth of 12% year-over-year from its health services, and strong sales in pharmacy, contributing to a year-to-date stock increase of 58%.
Healthcare as not performed well this year.
Technology attracting lots of investor money in the short term.
Long term, demand for healthcare is strong.
Recent M&A and company re-organization has negatively impacted share price.
Current share price presenting value - however waiting to see how company stabilizes.
Benefited during Covid, now fallen off. Diversified. Attractive multiple. Keeps acquiring to broaden its offerings. Not sure what catalyst is to get valuation multiple up. She owns other companies in healthcare.